Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.

Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, Ochoa MT, Seja E, Villanueva A, Oseguera DK, Straatsma BR, Cochran AJ, Glaspy JA, Hui L, Marincola FM, Wang E, Economou JS, Gomez-Navarro J.

Clin Cancer Res. 2009 Oct 1;15(19):6267-76. doi: 10.1158/1078-0432.CCR-09-1254. Epub 2009 Sep 29.

PMID:
19789309
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.

Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J.

J Immunother. 2006 Sep-Oct;29(5):545-57.

PMID:
16971810
[PubMed - indexed for MEDLINE]
3.

Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy.

Ribas A, Glaspy JA, Lee Y, Dissette VB, Seja E, Vu HT, Tchekmedyian NS, Oseguera D, Comin-Anduix B, Wargo JA, Amarnani SN, McBride WH, Economou JS, Butterfield LH.

J Immunother. 2004 Sep-Oct;27(5):354-67.

PMID:
15314544
[PubMed - indexed for MEDLINE]
4.

Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.

Panelli MC, Wunderlich J, Jeffries J, Wang E, Mixon A, Rosenberg SA, Marincola FM.

J Immunother. 2000 Jul-Aug;23(4):487-98.

PMID:
10916759
[PubMed - indexed for MEDLINE]
5.

Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen.

Smithers M, O'Connell K, MacFadyen S, Chambers M, Greenwood K, Boyce A, Abdul-Jabbar I, Barker K, Grimmett K, Walpole E, Thomas R.

Cancer Immunol Immunother. 2003 Jan;52(1):41-52. Epub 2002 Nov 13.

PMID:
12536239
[PubMed - indexed for MEDLINE]
6.

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.

Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, Sian S, Nichol G, Davis T, Keler T, Yellin M, Weber J.

J Clin Oncol. 2005 Feb 1;23(4):741-50. Epub 2004 Dec 21.

PMID:
15613700
[PubMed - indexed for MEDLINE]
Free Article
7.

Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.

Lesimple T, Neidhard EM, Vignard V, Lefeuvre C, Adamski H, Labarrière N, Carsin A, Monnier D, Collet B, Clapisson G, Birebent B, Philip I, Toujas L, Chokri M, Quillien V.

Clin Cancer Res. 2006 Dec 15;12(24):7380-8.

PMID:
17189411
[PubMed - indexed for MEDLINE]
Free Article
8.

Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.

Butterfield LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, Yang JQ, Vu HT, Seja E, Oseguera DK, Potter DM, Glaspy JA, Economou JS, Ribas A.

J Immunother. 2008 Apr;31(3):294-309. doi: 10.1097/CJI.0b013e31816a8910.

PMID:
18317358
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial.

Oshita C, Takikawa M, Kume A, Miyata H, Ashizawa T, Iizuka A, Kiyohara Y, Yoshikawa S, Tanosaki R, Yamazaki N, Yamamoto A, Takesako K, Yamaguchi K, Akiyama Y.

Oncol Rep. 2012 Oct;28(4):1131-8. doi: 10.3892/or.2012.1956. Epub 2012 Aug 7.

PMID:
22895835
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.

Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA.

Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7. Epub 2003 Jun 25.

PMID:
12826605
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma.

von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B, Ribas A.

J Transl Med. 2009 May 20;7:35. doi: 10.1186/1479-5876-7-35.

PMID:
19457253
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J.

J Clin Oncol. 2005 Dec 10;23(35):8968-77. Epub 2005 Oct 3.

PMID:
16204013
[PubMed - indexed for MEDLINE]
Free Article
13.

Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination.

Tarhini AA, Butterfield LH, Shuai Y, Gooding WE, Kalinski P, Kirkwood JM.

J Immunother. 2012 Nov-Dec;35(9):702-10. doi: 10.1097/CJI.0b013e318272569b.

PMID:
23090079
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.

Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G.

Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4712-7. Epub 2003 Apr 7.

PMID:
12682289
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon.

Banchereau J, Ueno H, Dhodapkar M, Connolly J, Finholt JP, Klechevsky E, Blanck JP, Johnston DA, Palucka AK, Fay J.

J Immunother. 2005 Sep-Oct;28(5):505-16.

PMID:
16113607
[PubMed - indexed for MEDLINE]
16.

Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma.

Lau R, Wang F, Jeffery G, Marty V, Kuniyoshi J, Bade E, Ryback ME, Weber J.

J Immunother. 2001 Jan-Feb;24(1):66-78.

PMID:
11211150
[PubMed - indexed for MEDLINE]
17.

Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients.

Bedrosian I, Mick R, Xu S, Nisenbaum H, Faries M, Zhang P, Cohen PA, Koski G, Czerniecki BJ.

J Clin Oncol. 2003 Oct 15;21(20):3826-35.

PMID:
14551301
[PubMed - indexed for MEDLINE]
Free Article
18.

Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells.

Vonderheide RH, LoRusso PM, Khalil M, Gartner EM, Khaira D, Soulieres D, Dorazio P, Trosko JA, Rüter J, Mariani GL, Usari T, Domchek SM.

Clin Cancer Res. 2010 Jul 1;16(13):3485-94. doi: 10.1158/1078-0432.CCR-10-0505. Epub 2010 May 17.

PMID:
20479064
[PubMed - indexed for MEDLINE]
Free Article
19.

Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report.

Dillman RO, Selvan SR, Schiltz PM, McClay EF, Barth NM, DePriest C, de Leon C, Mayorga C, Cornforth AN, Allen K.

Cancer Biother Radiopharm. 2009 Jun;24(3):311-9. doi: 10.1089/cbr.2008.0599.

PMID:
19538053
[PubMed - indexed for MEDLINE]
20.

Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma.

Straatsma BR, Nusinowitz S, Young TA, Gordon LK, Chun MW, Rosen C, Seja E, Economou JS, Glaspy JA, Bozon V, Gomez-Navarro J, Ribas A.

Am J Ophthalmol. 2007 Jun;143(6):958-969. Epub 2007 Apr 16.

PMID:
17434437
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk